TRIPLE-NEGATIVE BREAST CARCINOMA

This study tests a DNA-based vaccine called STEMVAC in 33 people with early-stage triple negative breast cancer. The vaccine aims to teach the immune system to recognize and attack proteins found on breast cancer stem cells. The main goal is to see if the vaccine triggers a stron…

This early-phase study tested a vaccine (p53MVA) plus the drug pembrolizumab in 11 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to see if the combination is safe and can boost the immune system to attack cancer cells. Participant…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) is better than capecitabine at preventing breast cancer from coming back in people with a specific type of triple-negative breast cancer (basal-like) that was not completely removed by initial chemoth…

This study tests whether combining an immunotherapy drug (avelumab) with other medications can help shrink or control advanced triple-negative breast cancer that has spread or cannot be removed by surgery. About 145 adults with stage IV or recurrent triple-negative breast cancer …

This early-phase study tests two oral drugs, ZEN003694 and binimetinib, together in people with advanced solid tumors that have RAS gene changes or triple-negative breast cancer. The goal is to find the safest dose and understand side effects. About 42 adults whose cancer has spr…

This study tests two drug combinations (olaparib plus either vistusertib or capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The goal is to find the safest dose and see if the drugs can control tumor growth. About 159 adults…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab after standard chemotherapy helps prevent triple-negative breast cancer from returning. About 1,155 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or a placebo. …

This early-phase trial tests a new drug (BAY 1895344) combined with standard chemotherapy in people with advanced solid tumors, especially bladder cancer. The goal is to find the safest dose and see how well the combination works. About 74 adults with cancers like lung, bladder, …

This early-phase study tests a drug called berzosertib combined with radiation therapy for people with certain types of breast cancer that no longer respond to chemotherapy. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors better than …

This study tested whether giving chemotherapy (paclitaxel and cyclophosphamide) with or without the targeted drug trastuzumab before surgery helps shrink breast cancer tumors in 92 women with early-stage or locally advanced breast cancer. The goal was to see if the treatment redu…

This study tested a combination of two drugs, cediranib and olaparib, in 155 people whose ovarian, fallopian tube, peritoneal, or triple-negative breast cancer had come back. The goal was to see if the combo was safe and worked better than olaparib alone at slowing cancer growth.…

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy before surgery helps shrink tumors more than chemo alone in people with stage II-III triple negative breast cancer. About 67 participants received either chemo alone or chemo plus atezol…

This study tests whether the immunotherapy drug pembrolizumab can help control advanced breast cancer in patients whose disease has not worsened after initial chemotherapy. It includes 71 adults with either inflammatory breast cancer or triple-negative breast cancer that has spre…

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can increase immune cell activity in breast tumors. It involves 46 people with locally advanced HER2-negative breast cancer, divided by hormone receptor status. The…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …

This early-phase study tests a new combination of two drugs—veliparib and carboplatin—in people with HER2-negative breast cancer that has spread. The goal is to find the safest dose and see if the combo can shrink tumors. About 44 adults with advanced or returning breast cancer w…

This study compares two different chemotherapy combinations given before surgery for a fast-growing, hard-to-treat type of breast cancer called triple-negative inflammatory breast cancer. Researchers want to see if adding a targeted drug called panitumumab to standard chemotherap…

This study looks at whether advanced breast imaging scans can predict how well chemotherapy is working in people with triple negative breast cancer. About 96 participants will get special MRI and molecular breast imaging scans before, during, and after chemo. The goal is to see i…

This study looks at whether a blood test that finds tiny bits of tumor DNA can help doctors know if early-stage breast cancer patients still have cancer cells after treatment. About 350 people with stage I-III breast cancer will give blood samples and tumor tissue. The goal is to…

This study looks at whether watching an online genetics video, with or without phone counseling, helps reduce stress about cancer risk in women with triple-negative breast cancer. About 5,200 women aged 30 or older who have at least one ovary and a history of early or triple-nega…

This study was designed to see if an online mental health program could help women with advanced gynecologic or breast cancer manage their fear of the cancer returning or getting worse. The program would have been compared to standard educational materials. However, the trial was…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will store and study these samples over time to learn how cancer changes and why some treatments stop working. The goal is to improve future …